Curated News
By: NewsRamp Editorial Staff
September 17, 2024
Crucial Decision Pending for Cardio Diagnostics' Heart Disease Tests
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Cardio Diagnostics is awaiting a crucial decision that could be a major factor in the commercial success of its flagship heart disease tests.
- The company attended a meeting hosted by the Centers for Medicare and Medicaid Services (CMS) to present pricing recommendations for its two cutting-edge tests: Epi+Gen CHD and PrecisionCHD.
- Cardio Diagnostics' advanced diagnostic tools have the potential to bring its heart disease tests one step closer to being widely accessible to Medicare patients, potentially saving the lives of millions.
- Cardio Diagnostics' AI-powered blood-based DNA test, Epi+Gen CHD, evaluates genetic and epigenetic markers to assess the three-year risk for a symptomatic CHD event.
Impact - Why it Matters
This news matters because Cardio Diagnostics' AI-powered tests have the potential to revolutionize the prevention, detection, and management of coronary heart disease. The CMS's decision could make these tests widely accessible to Medicare patients, potentially saving the lives of millions.
Summary
Cardio Diagnostics (NASDAQ: CDIO), a company using AI to revolutionize cardiovascular disease prevention, is awaiting a crucial decision from the Centers for Medicare and Medicaid Services regarding the pricing of its Epi+Gen CHD and PrecisionCHD tests. The company's CEO is committed to making these cutting-edge tests accessible to Medicare beneficiaries, as heart disease is the leading cause of death among this demographic. The CMS is expected to release its proposed payment determinations in September, with final determinations in November.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Crucial Decision Pending for Cardio Diagnostics' Heart Disease Tests
